COST EFFECTIVENESS ANALYSIS BETWEEN ASPIRIN AND CITICOLINE IN STROKE PATIENT IN PROF DR MARGONO SOEKARJO HOSPITAL PURWOKERTO

Didik Setiawan

Abstract


Stroke is the third highest cause of death after heart disease and cancer. An appropriate therapy decision is important because it related to many factors such as cost and quality of life. Most of Indonesian physicians’ use citicoline and Aspirin for stroke patients. A Cohort Retrospective study was performed to 40 patients with aspirin and 77 patients with citicoline. Secondary data such as cost, length of stay (LoS) was collected from medical records. Furthermore, patient health level was measured by National Institute of Health Stroke Scale (NIHSS) which was collected from patient directly. The average of patients’ age was 60.59±11.31 years old. The NIHSS showed no significant difference between aspirin (2.58±2.93) and citicoline (3.10±2.90) groups. Otherwise, LoS was different between two groups (p value 0.000). The average of total cost in aspirin group (IDR 2,593,250.00) was lower than citicoline groups (IDR 11,384,210.00) and the differences were statistically siginificant. The Incremental Cost Effectiveness Ratio (ICER) between aspirin compared to citicoline was IDR 16,905,692.31 per quality of life. Aspirin was strongly dominated to citicoline in cost, LoS and NIHSS. 


Full Text:

PDF (pp.105)

References


Albert MJ., 2012, Citicoline did not improve recovery at 90 days after moderate-to-severe acute ischemicstroke, Ann Intern Med, 157 (6): JC3-13.

[CDC] Centers for Disease Control and Prevention, 2012, Prevalence of Stroke — United States, 2006–2010, Morbidity and Mortality Weekly Report.

[CDC] Centers for Disease Control and Prevention, 2012, Interpreting CEA Result. http://www.cdc.gov [1 July 2013].

Chairangsarit P., Sithinamsuwan P., Niyasom S., et al, 2005, Comparison between Aspirin Combined with Dipyridamole versus Aspirin Alone within 48 Hours after Ischemic Stroke Event for Prevention of Recurrent Stroke and Improvement of Neurological Function : A Preliminary Study, Division of Neurology, Department of Medicine, Phramongkutklao Hospital.

Chang KC., Mei CT., Hsu HW., et al, 2002, Prediction of Length of Stay of First-Ever Ischemic Stroke, American Heart Association, Inc.

Coleman CI., Straznitskas AD., Sobieraj DM., Kluger J., Anglade MW. 2012,Cost-effectiveness of Clopidogrel Plus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation in Whom Warfarin Is Unsuitable, Am J Cardiol. 109(7): 1020-5.

Conant, R., Schauss, A.G., 2004, Therapeutic Applications of Citicoline for Stroke and Cognitive Dysfunction in the Elderly : A Review of the Literature dalam Alternative Medicine Review, Thorne Research, Inc.

Dávalos A., Alvarez-Sabín J., Castillo J., Díez-Tejedor E., et al., 2012 Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). 2012, Lancet;380(9839):349-57.

[Depkes RI] Departemen Kesehatan Republik Indonesis, 2006, Profil Kesehatan Provinsi Jawa Tengah Tahun 2006. http://www.depkes.go.id. [1 December 2012]

Fonarow GC., Mathew, JR., Xin Z., et al, 2010, Age-Related Differences in Characteristics, Performance Measures, Treatmeant Trends, and Outcomes in Patients With Ischemic Stroke, American Heart Association, Inc.

Goldstein, LB., Cheryl DB., Robert JA., et al, 2011, Guidelines for the Primary Prevention of Stroke, American Heart Association, Inc.

Gorelick PB., Dejuran R., Michael K., et al, 2003, Aspirin and Ticlodipine for Prevention of Reccurent Stroke in Black Patients, American Medical Association.

Luk HH., Pang J., Li LS., Ng M., 2005, Use of Antiplatelet Drugs in The Stroke Unit of a Hongkong Hospital, Departement of Pharmachy, Tung Wah Hospital.

Meyer BC., Thomas MH., Christy MJ., Patrick DL., 2002, Modified National Institutes of Health Stroke Scale for Use in Stroke Clinical Trials : Prospective Reliability and Validity, American Heart Association.

Mittal M., Goel D., Bansal KK., Puri P., Edaravone-Citicoline Comparative Study in Acute Ischemic Stroke (ECCS- AIS), Associate Professor neurology, Professor neurology, Professor neurosurgery, Postgraduate in Department of General medicine, HIHT University, Swami ram nagar, Doiwala, Dehradun.

Sofwan R., 2010, Anda Bertanya Dokter Menjawab : Stroke dan Rehabilitasi Pasca-Stroke, Jakarta : PT. Bhuana Ilmu Populer .

Sukemi, 2011, Evaluasi Penggunaan Obat Terapi Pemeliharaan Stroke pada Pasien Rawat Inap di RSUD. Dr. Moewardi Surakarta Tahun 2010 [skripsi], Surakarta, Fakultas Farmasi, Universitas Muhammadiyah Surakarta.




DOI: http://dx.doi.org/10.14499/indonesianjpharm25iss2pp105

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

                                    
 
web
analytics View My Stats